About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine.
Optum’s biosimilar business to exclude brand-name Stelara, Humira in 2025
Optum Rx is moving into the biosimilar business with a company it’s calling Nuvaila, and it’s starting out with biosimilars to AbbVie’s blockbuster rheumatoid arthritis